2nd Quarter - Report

WINNING STRATEGIES WASHINGTON for KALEO

Period 2nd Quarter 2017 Filed Jul 18, 2017 Signed by Donna F. Mullins, Managing Partner

Official filing
Firm
WINNING STRATEGIES WASHINGTON
Client
KALEO
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Pharmaceutical drug development including epinephrine for anaphylaxis

LobbyistCovered position, as disclosed
CARL CHIDLOW —
MICHAEL A MEROLA —
DONNA MULLINS —
CHARLA PENN —
CHELSEY PENROD HICKMAN —
ROBERT ZUCKER —

Contacted: Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Reducing opioid overdose deaths; implementation of HR 3680/S. 2256 provisions related to naloxone included in the conference report on S. 524, the Comprehensive Addiction and Recovery Act; Pharmaceutical drug development, including epinephrine for anaphylaxis. S.771 Improving Access to Affordable Prescription Drugs Act, S.469 Affordable And Safe Prescription Drug Importation Act.

LobbyistCovered position, as disclosed
CARL CHIDLOW —
MICHAEL A MEROLA —
DONNA MULLINS —
CHARLA PENN —
CHELSEY PENROD HICKMAN —
ROBERT ZUCKER —

Contacted: SENATE; Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES

Bills named: S. 524 (115th), H.R. 3680 (115th), S. 469 (115th), S. 2256 (115th), S. 771 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.